BBP-631 Drug Market
"BBP-631 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about BBP-631 for Congenital Adrenal Hyperplasia (CAH) in the seven major markets. A detailed picture of the BBP-631 for CAH in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 –2032 is provided in this report along with a detailed description of the BBP-631 for CAH. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the BBP-631 market forecast analysis for CAH in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in CAH.
BBP-631 Drug Summary
BBP-631 is an AAV5 gene therapy developed by Adrenas therapeutics, which is a subsidiary of BridgeBio, to treat CAH due to 21-hydroxylase deficiency at its source. BBP-631 is designed to deliver a functional copy of the 21-hydroxylase gene and has been shown through multiple preclinical studies to result in efficient and persistent delivery to the adrenal gland, where hormones are naturally made. According to the company, if successful, BBP-631 may restore the body’s hormone and steroid balance by enabling people with CAH to make their own cortisol and aldosterone naturally. It could also allow people with CAH to significantly eliminate their daily glucocorticoid or mineralocorticoid doses, which is the current standard of care for patients.
The company has initiated the Phase I/II clinical trial by dosing the first patient, and the results are anticipated in the second half of 2022.
In May 2021, the companies received the fast track designation from FDA. Additionally, BBP-631 was granted Rare Pediatric Disease Designation by the FDA and has received Orphan Drug Designation by the FDA and European Medicines Agency (EMA).
Scope of the BBP-631 Market Report
The report provides insights into:
• A comprehensive product overview including the BBP-631 description, mechanism of action, dosage and administration, research and development activities in CAH.
• Elaborated details on BBP-631 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the BBP-631 research and development activities in CAH across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around BBP-631.
• The report contains forecasted sales of BBP-631 for CAH till 2032.
• Comprehensive coverage of the late-stage emerging therapies for CAH.
• The report also features the SWOT analysis with analyst views for BBP-631 in CAH.
BBP-631 Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
BBP-631 Analytical Perspective by DelveInsight
• In-depth BBP-631 Market Assessment
This report provides a detailed market assessment of BBP-631 for CAH in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data of BBP-631.
• BBP-631 Clinical Assessment
The report provides the clinical trials information of BBP-631 for CAH covering trial interventions, trial conditions, trial status, start and completion dates.
BBP-631 Report Highlights
• In the coming years, the market scenario for CAH is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence BBP-631 dominance.
• Other emerging products for CAH are expected to give tough market competition to BBP-631 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of BBP-631 in CAH.
• Our in-depth analysis of the forecasted sales data of BBP-631 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the BBP-631 in CAH.
Key Questions
• What is the product type, route of administration and mechanism of action of BBP-631?
• What is the clinical trial status of the study related to BBP-631 in CAH and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the BBP-631 development?
• What are the key designations that have been granted to BBP-631 for CAH?
• What is the forecasted market scenario of BBP-631 for CAH?
• What are the forecasted sales of BBP-631 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to BBP-631 for CAH?
• Which are the late-stage emerging therapies under development for the treatment of CAH?
